Skip to main content

Table 3 Surrogate markers follow-up (Peak levels) during ICU stay

From: Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study

Surrogate markers

Enoxaparin

UFH

P-value ^

beta coefficient (Estimates) (95%CI)

P-value $*

D-dimer level (mg/l), Median (Q1, Q3)a

2.7 (0.89, 18.90)

3.9 (2.01, 17.72)

0.22^

0.16 (-0.42,0.74)

0.59

Fibrinogen Level, Median (Q1, Q3)a

5.8 (4.33, 8.36)

6.1 (4.59, 7.37)

0.72*

-0.04 (-0.24,0.17)

0.72

C-reactive protein (CRP), Median (Q1, Q3)a

123.0 (48.30, 231.00)

177.5 (104.00, 258.00)

0.04^

0.17 (-0.16,0.51)

0.31

Erythrocyte sedimentation rate (ESR), Median (Q1, Q3)a

71.0 (50.00, 108.00)

70.0 (40.00, 102.00)

0.51*

-0.08 (-0.73,0.57)

0.80

  1. aDenominator of the percentage is the total number of patients
  2. *T -Test / ^ Wilcoxon rank sum test is used to calculate the P-value
  3. $* Generalized linear model is used to calculate estimates and p-value